Novo was informed last week, that “the ongoing facility remediation acitivities are the cause for extension of the agency's review,” a press release from Novo states.
Novo had submitted a BLA, Biological License Application, to FDA for treament of haemophilia A in adult and pediatric patients in September last year with an anticipated regulatory decision in the third quarter this year.
BREAKING